Strategic Acquisitions and Partnerships Drive Xoma’s Growth: A Buy Recommendation
I'm PortAI, I can summarize articles.
Joseph Pantginis from H.C. Wainwright maintains a Buy rating on Xoma, with a $97.00 price target, citing strategic acquisitions and partnerships, including Generation Bio's collaboration with Moderna. This move is expected to enhance Xoma's revenue streams. Pantginis, a 5-star analyst, highlights Xoma's creative asset management and non-dilutive cash generation capabilities. Leerink Partners also maintains a Buy rating with a $45.00 target. Pantginis covers the Healthcare sector, focusing on stocks like Kura Oncology and Celldex.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments